We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS).
- Authors
Chen, Chung-Hwan; Elsalmawy, Abdulaziz H.; Ish-Shalom, Sophia; Lim, Seung-Jae; AlAli, Nadia S.; Cunha-Borges, Joao L.; Yang, Huilin; Casas, Noemi; Altan, Lale; Belaya, Zhanna; Marin, Fernando; Moll, Thomas; Gurbuz, Sirel; Brnabic, Alan; Pavo, Imre; Florez, Sandra
- Abstract
The Asian and Latin America Fracture Observational Study (ALAFOS) is a prospective, observational, single-arm study conducted in 20 countries across Asia, Latin America and the Middle East. ALAFOS evaluated new clinical vertebral and non-vertebral fragility fractures in relation to time on teriparatide, in postmenopausal women with osteoporosis in real-life clinical practice. Clinical fragility fractures, back pain, and health-related quality of life (HRQoL) were recorded in 6-month intervals for ≤ 24 months during teriparatide treatment and up to 12-months post-treatment. Data were analysed with piecewise exponential regression with inverse probability weighting for time to event outcomes and mixed-model repeated measures for back pain and HRQoL. 3054 postmenopausal women started teriparatide and attended ≥ one follow-up visit (mean [SD] age 72.5 [10.4] years). The median (95% CI) time to treatment discontinuation was 22.0 months (21.2, 22.8). During the treatment period, 111 patients (3.6%) sustained 126 clinical fractures (2.98 fractures/100 patient-years). Rates of new clinical fragility fractures were significantly decreased during the > 6–12, > 12–18, and > 18–24-month periods, as compared with the first 6 months of treatment (hazard ratio [HR] 0.57; 95% CI 0.37, 0.88; p = 0.012; HR 0.35; 95% CI 0.19, 0.62; p < 0.001; HR 0.43; 95% CI 0.23, 0.83; p = 0.011; respectively). Patients also reported an improvement in back pain and HRQoL (p < 0.001). These results provide data on the real-world effectiveness of teriparatide in the ALAFOS regions and are consistent with other studies showing reduction of fractures after 6 months of teriparatide treatment. These results should be interpreted in the context of the noncontrolled design of this observational study.
- Subjects
MIDDLE East; ASIA; OSTEOPOROSIS in women; POSTMENOPAUSE; SCIENTIFIC observation; TERMINATION of treatment; BACKACHE; CLIMACTERIC; FRACTURE healing
- Publication
Calcified Tissue International, 2022, Vol 110, Issue 1, p74
- ISSN
0171-967X
- Publication type
Article
- DOI
10.1007/s00223-021-00895-4